Swisher, Elizabeth M
Lin, Kevin K
Oza, Amit M
Scott, Clare L
Giordano, Heidi
Sun, James
Konecny, Gottfried E
Coleman, Robert L
Tinker, Anna V
O'Malley, David M
Kristeleit, Rebecca S
Ma, Ling
Bell-McGuinn, Katherine M
Brenton, James D
Cragun, Janiel M
Oaknin, Ana
Ray-Coquard, Isabelle
Harrell, Maria I
Mann, Elaina
Kaufmann, Scott H
Floquet, Anne
Leary, Alexandra
Harding, Thomas C
Goble, Sandra
Maloney, Lara
Isaacson, Jeff
Allen, Andrew R
Rolfe, Lindsey
Yelensky, Roman
Raponi, Mitch
McNeish, Iain A
Funding for this research was provided by:
Clovis Oncology
US Department of Defense Ovarian Cancer Research Program (OC120506)
V Foundation Translational Award
Stand Up To Cancer—Ovarian Cancer Research Fund Alliance—National Ovarian Cancer Coalition Dream Team Translational Research Grant (SU2C-AACR-DT16-15)
Ann Rife Cox Chair in Gynecology
Judy Reis (Al Pisani) Ovarian Cancer Research Fund (RLC)
UCH/UCL Biomedical Research Centre (RK)
Experimental Cancer Medicine Centres at UCL (RK)
This article is maintained by: Elsevier
Article Title: Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Journal Title: The Lancet Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1470-2045(16)30559-9
CrossRef DOI link to the associated document: https://doi.org/10.1016/S1470-2045(16)30621-0
Content Type: article
Copyright: © 2016 Elsevier Ltd. All rights reserved.